Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for atypical pantothenate kinase-associated neurodegeneration.
5 publications have been identified in PubMed for atypical pantothenate kinase-associated neurodegeneration. Research spans Other (20%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Asuncion RMD (2026). [PMID: 28613462](https://pubmed.ncbi.nlm.nih.gov/28613462/). *Unknown Journal*. [Review / Meta-Analysis]
Van Opstal J (2026). [PMID: 41855754](https://pubmed.ncbi.nlm.nih.gov/41855754/). *Parkinsonism Relat Disord*. [Other]
Vardarajan BN (2025). [PMID: 40799282](https://pubmed.ncbi.nlm.nih.gov/40799282/). *Brain communications*. [Epidemiology / Natural History]
Saini A (2024). [PMID: 38506547](https://pubmed.ncbi.nlm.nih.gov/38506547/). *Movement disorders : official journal of the Movement Disorder Society*. [Basic Science / Preclinical]
Hong G (2024). [PMID: 39479227](https://pubmed.ncbi.nlm.nih.gov/39479227/). *Frontiers in human neuroscience*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 4:38 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning atypical pantothenate kinase-associated neurodegeneration
Updated Sep 17, 2026
A new study demonstrates that a selective PanK3 activator successfully restores coenzyme A levels in cellular and mouse models of pantothenate kinase-associated neurodegeneration. This research could pave the way for novel therapeutic strategies targeting this rare neurodegenerative condition.